Sanofi (NASDAQ:SNY) Short Interest Up 35.2% in August

Key Points

• Sanofi's short interest surged by 35.2% in August, reaching a total of 4,420,000 shares short sold.
• Wall Street analysts have a consensus rating of "Buy" for Sanofi, with a target price of $62.67, following upgrades from multiple firms.
• Despite reporting earnings per share of $0.90, Sanofi missed analysts' expectations by $0.06 while also experiencing a 7.0% decline in quarterly revenue year-over-year.

Sanofi (NASDAQ:SNY - Get Free Report) was the target of a significant growth in short interest during the month of August. As of August 15th, there was short interest totaling 4,420,000 shares, agrowthof35.2% from the July 31st total of 3,270,000 shares. Approximately0.2% of the company's shares are short sold. Based on an average trading volume of 2,280,000 shares, the days-to-cover ratio is presently 1.9 days. Based on an average trading volume of 2,280,000 shares, the days-to-cover ratio is presently 1.9 days. Approximately0.2% of the company's shares are short sold.

Wall Street Analyst Weigh In

SNY has been the topic of a number of research analyst reports. Wall Street Zen raised shares of Sanofi from a "hold" rating to a "buy" rating in a research report on Saturday, August 2nd. Guggenheim reissued a "buy" rating on shares of Sanofi in a research report on Tuesday, June 3rd. Barclays reissued an "overweight" rating on shares of Sanofi in a research report on Wednesday, July 2nd. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a "hold" rating to a "buy" rating in a research report on Tuesday, September 2nd. Finally, JPMorgan Chase & Co. raised shares of Sanofi from a "neutral" rating to an "overweight" rating in a research report on Friday, August 8th. Three research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, Sanofi currently has a consensus rating of "Buy" and a consensus price target of $62.67.

Sanofi Trading Down 0.2%

Shares of SNY stock opened at $46.41 on Monday. The company has a 50 day moving average of $48.81 and a 200-day moving average of $51.36. The company has a quick ratio of 0.94, a current ratio of 1.27 and a debt-to-equity ratio of 0.19. Sanofi has a 12-month low of $44.73 and a 12-month high of $60.12. The firm has a market cap of $113.97 billion, a P/E ratio of 11.19, a PEG ratio of 1.10 and a beta of 0.51.

Sanofi (NASDAQ:SNY - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The company reported $0.90 earnings per share for the quarter, missing analysts' consensus estimates of $0.96 by ($0.06). Sanofi had a net margin of 21.47% and a return on equity of 16.86%. The business had revenue of $11.34 billion during the quarter, compared to analysts' expectations of $9.91 billion. During the same quarter in the prior year, the firm posted $1.73 earnings per share. The firm's quarterly revenue was down 7.0% on a year-over-year basis. Sell-side analysts anticipate that Sanofi will post 4.36 earnings per share for the current year.

Institutional Trading of Sanofi

Hedge funds have recently made changes to their positions in the stock. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Sanofi by 124.0% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 24,131 shares of the company's stock worth $1,344,000 after acquiring an additional 13,358 shares during the last quarter. Axxcess Wealth Management LLC lifted its holdings in shares of Sanofi by 130.5% during the 1st quarter. Axxcess Wealth Management LLC now owns 10,234 shares of the company's stock worth $568,000 after acquiring an additional 5,794 shares during the last quarter. Ballentine Partners LLC lifted its holdings in shares of Sanofi by 68.7% during the 1st quarter. Ballentine Partners LLC now owns 26,063 shares of the company's stock worth $1,445,000 after acquiring an additional 10,617 shares during the last quarter. Sowell Financial Services LLC bought a new stake in shares of Sanofi during the 1st quarter worth $328,000. Finally, Farther Finance Advisors LLC lifted its holdings in shares of Sanofi by 66.2% during the 1st quarter. Farther Finance Advisors LLC now owns 6,215 shares of the company's stock worth $338,000 after acquiring an additional 2,476 shares during the last quarter. 14.04% of the stock is owned by institutional investors.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.